Kepler Capital analyst Oliver Reinberg maintained a Buy rating on Qiagen (NYSE:QGEN) NV on Tuesday, setting a price target of EUR51, which is approximately 27.86% above the present share price of $47.94.
Reinberg expects Qiagen NV to post earnings per share (EPS) of $0.93 for the second quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Hold rating of shares in Qiagen, with an average price target of $57.81.
The analysts price targets range from a high of $70 to a low of $42.07.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $571.23 million and a net profit of $168.59 million. The company's market cap is $10.92 billion.
According to TipRanks.com, Kepler Capital analyst Oliver Reinberg is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.3% and a 42.00% success rate.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.